Arrowhead Pharma (ARWR) ENaC News 'Not Thesis Changing', RBC Says; PT Lowered to $83
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Arrowhead Pharma (ARWR) Defended at Citi Following ENAC Setback
July 2, 2021 10:02 AM EDTCiti analyst Mohit Bansal came out to defend Arrowhead Pharma (NASDAQ: ARWR) amid the sharp drop in the stock after pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with... More
Arrowhead (ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study
July 2, 2021 7:45 AM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Falls 22% After Pausing ARO-ENaC Phase 1/2 Clinical Study
... MoreArrowhead Pharmaceuticals Inc. (ARWR) Pauses ARO-ENaC Phase 1/2 Clinical Study
July 2, 2021 7:32 AM EDTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), after receiving a preliminary update from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation. The company has instructed investigators to pause new screening, enrollment, and any further dosing of investigational ARO-ENaC pending additional data from the ongoing chronic rat toxicology... More
